Apixaban

From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is developing and not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.

Apixaban is an oral anticoagulant. Apixaban is an oral inhibitor of clotting Factor Xa inhibitor.

History

As of 8/2011, apixiban is not approved for use in the United States.

Pharmacology

Administration

Distribution

Metabolism

Hepatic metabolism.

Excretion

Toxicity

Clinical use

Apixaban can prevent can prevent embolism and thrombosis during perioperative care according to randomized controlled trials of knee[1] and hip[2] surgery.

Apixaban may also reduce embolism better than warfarin in atrial fibrillation.[3] [4]

Randomized controlled trials of apixaban for atrial fibrillation.[3] [4]
Trial Patients Intervention Comparison Outcome Results
Intervention Control
AVERROES[4]
2011
5599 patients
• All had contraindications to warfarin
apixaban 5 mg twice daily aspirin 81 to 324 mg per day stroke or systemic embolism at 1.1 years 1.6% per year 3.7% per year
ARISTOTLE[3]
2011
18,201 patients apixaban 5 mg twice daily warfarin (target INR 2.0 to 3.0 stroke or systemic embolism at 1.3 years 1.3% per year 1.6% per year

External links

The most up-to-date information about Apixaban and other drugs can be found at the following sites.


References

  1. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ (2009). "Apixaban or enoxaparin for thromboprophylaxis after knee replacement.". N Engl J Med 361 (6): 594-604. DOI:10.1056/NEJMoa0810773. PMID 19657123. Research Blogging.
  2. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM et al. (2010). "Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.". N Engl J Med 363 (26): 2487-98. DOI:10.1056/NEJMoa1006885. PMID 21175312. Research Blogging.
  3. 3.0 3.1 3.2 Granger, Christopher B.; John H. Alexander, John J.V. McMurray, Renato D. Lopes, Elaine M. Hylek, Michael Hanna, Hussein R. Al-Khalidi, Jack Ansell, Dan Atar, Alvaro Avezum, M. Cecilia Bahit, Rafael Diaz, J. Donald Easton, Justin A. Ezekowitz, Greg Flaker, David Garcia, Margarida Geraldes, Bernard J. Gersh, Sergey Golitsyn, Shinya Goto, Antonio G. Hermosillo, Stefan H. Hohnloser, John Horowitz, Puneet Mohan, Petr Jansky, Basil S. Lewis, Jose Luis Lopez-Sendon, Prem Pais, Alexander Parkhomenko, Freek W.A. Verheugt, Jun Zhu, Lars Wallentin (2011-08). "Apixaban versus Warfarin in Patients with Atrial Fibrillation". New England Journal of Medicine: 110827230022006. DOI:10.1056/NEJMoa1107039. ISSN 0028-4793. Retrieved on 2011-08-28. Research Blogging.
  4. 4.0 4.1 4.2 Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. (2011). "Apixaban in patients with atrial fibrillation.". N Engl J Med 364 (9): 806-17. DOI:10.1056/NEJMoa1007432. PMID 21309657. Research Blogging. Review in: Ann Intern Med. 2011 Apr 19;154(8):JC4-3